» Articles » PMID: 23915322

Frequent Use of Blood-saving Measures in Elective Orthopaedic Surgery: a 2012 Dutch Blood Management Survey

Overview
Publisher Biomed Central
Specialties Orthopedics
Physiology
Date 2013 Aug 7
PMID 23915322
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Blood loss in hip and knee arthroplasties may necessitate allogeneic blood transfusions. Different blood-saving measures (BSMs) were introduced to reduce these transfusions. Purpose of the present study was to assess the frequency of BSM use, stratified by type and hospital setting of orthopaedic departments in the Netherlands.

Methods: An internet-based questionnaire was sent to all heads of orthopaedic departments of Dutch hospitals and private clinics (n = 99). Questions were asked on how often BSMs were used, reported on a 5-point Likert scale (never, almost never, regularly, almost always, always). In addition there were questions about discontinuation of anticoagulants preoperatively, the number of annually performed arthroplasties (size) and hospital setting.

Results: The survey was completed by 81 (82%) departments. BSMs used frequently (regularly, almost always, always) were erythropoietine (EPO), with 55 (68%) departments being frequent users; acute normovolemic hemodilution, used frequently in 26 (32%) departments; cell saver in 25 (31%) and postoperative drainage and re-infusion in 56 (69%) departments. When compared by size, frequent EPO use was more common in large departments (with 22 (88%) large departments being frequent users versus 13 (63%) small departments and 16 (55%) intermediate departments, p = 0.03). No differences by size or type were observed for other BSMs.

Conclusions: Compared with previous survey's there is a tremendous increase in use of BSMs. EPO and autologous blood salvage techniques are the most often used modalities. Costs might be saved if use of non-cost-effective BSMs is stopped.

Citing Articles

Hospital variation in allogeneic transfusion and extended length of stay in primary elective hip and knee arthroplasty: a cross-sectional study.

Voorn V, Marang-van de Mheen P, van der Hout A, So-Osman C, Elske van den Akker-van Marle M, Koopman-van Gemert A BMJ Open. 2017; 7(7):e014143.

PMID: 28729306 PMC: 5541495. DOI: 10.1136/bmjopen-2016-014143.


No benefit of autologous transfusion drains in total knee arthroplasty.

Schnurr C, Giannakopoulos I, Arbab D, Dargel J, Beckmann J, Eysel P Knee Surg Sports Traumatol Arthrosc. 2017; 26(5):1557-1563.

PMID: 28577064 DOI: 10.1007/s00167-017-4585-8.


The effectiveness of a de-implementation strategy to reduce low-value blood management techniques in primary hip and knee arthroplasty: a pragmatic cluster-randomized controlled trial.

Voorn V, Marang-van de Mheen P, van der Hout A, Hofstede S, So-Osman C, Elske van den Akker-van Marle M Implement Sci. 2017; 12(1):72.

PMID: 28558843 PMC: 5450044. DOI: 10.1186/s13012-017-0601-0.


Transfusion medicine as of 2014.

Lozano M, Cid J F1000Prime Rep. 2015; 6:105.

PMID: 25580259 PMC: 4229729. DOI: 10.12703/P6-105.


[Acute perioperative hemodilution without using hydroxyethyl starch : hemodynamic alterations under "controlled" hypovolemia].

Hofmann-Kiefer K, Chappell D, Jacob M, Schulke A, Helfen T, Anetzberger J Anaesthesist. 2014; 64(1):26-32.

PMID: 25380794 DOI: 10.1007/s00101-014-2398-4.


References
1.
Laupacis A, Fergusson D . Erythropoietin to minimize perioperative blood transfusion: a systematic review of randomized trials. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Transfus Med. 1999; 8(4):309-17. DOI: 10.1046/j.1365-3148.1998.00171.x. View

2.
Rao V, Dyga R, Bartels C, Waters J . A cost study of postoperative cell salvage in the setting of elective primary hip and knee arthroplasty. Transfusion. 2012; 52(8):1750-60. PMC: 3360121. DOI: 10.1111/j.1537-2995.2011.03531.x. View

3.
Alshryda S, Sarda P, Sukeik M, Nargol A, Blenkinsopp J, Mason J . Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg Br. 2011; 93(12):1577-85. DOI: 10.1302/0301-620X.93B12.26989. View

4.
Henry D, Carless P, Moxey A, OConnell D, Stokes B, Fergusson D . Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011; (3):CD001886. PMC: 4234031. DOI: 10.1002/14651858.CD001886.pub4. View

5.
Green W, Toy P, Bozic K . Cost minimization analysis of preoperative erythropoietin vs autologous and allogeneic blood donation in total joint arthroplasty. J Arthroplasty. 2008; 25(1):93-6. DOI: 10.1016/j.arth.2008.10.005. View